Ubretid

Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder[1].

Product Specifications

CAS Number

[15876-67-2]

Product Name Alternative

Distigmine (dibromide)

UNSPSC

12352005

Hazard Statement

H300, H412

Target

Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ubretid.html

Purity

99.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C)CCCCCCN(C)C(OC1=C[N+](C)=CC=C1)=O)OC2=C[N+](C)=CC=C2.[Br-].[Br-]

Molecular Formula

C22H32Br2N4O4

Molecular Weight

576.32

Precautions

H300, H412

References & Citations

[1]Isono S, et al. Ubretid (distigmine bromide) taken to treat urinary retention prolongs the effect of suxamethonium. J Anesth. 2008;22 (3) :337.|[2]Nakayama K, et al., Effect of distigmine bromide on the central cholinergic system. J Psychopharmacol. 2009 Mar;23 (2) :190-3.